Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
GlobeNewswire
· MP0712, a ^212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in..